Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)

No­var­tis of­floads five eye drugs in deal worth up to $175M

Eye care phar­ma com­pa­ny Har­row said this morn­ing that it’s ac­quir­ing the US rights to five dif­fer­ent drugs from the Swiss phar­ma No­var­tis for $130 mil­lion up­front, with $45 mil­lion more if one of the drugs lands on the mar­ket.

If the deal goes through, Har­row will hold ex­clu­sive use in the US for the four eye drop prod­ucts and one in­jectable drug.

The ad­di­tion­al $45 mil­lion will come if the steroid in­jec­tion Tries­ence hits the mar­ket, which is ex­pect­ed in the sec­ond half of next year, Har­row said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.